The Phase III CELESTIMO study, evaluating Lunsumio (mosunetuzumab) combined with lenalidomide, met its primary endpoint for relapsed or refractory follicular lymphoma (FL). This interim analysis revealed a statistically significant and clinically meaningful reduction in disease progression risk for patients who had received at least one prior treatment. The Lunsumio-based regimen also demonstrated a tolerable safety profile, simple dosing, and outpatient administration. These findings support the potential for improved clinical outcomes earlier in the treatment journey for FL patients. Data from the study will be submitted to health authorities and presented at an upcoming medical meeting. This confirmatory study is crucial for converting Lunsumio monotherapy's accelerated approval to full approval and securing an indication in second-line or later FL. Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody, already approved in over 60 countries for later-line FL. Roche is actively expanding Lunsumio's development, including an ongoing Phase III MorningLyte study in first-line FL. Follicular lymphoma is a common, slow-growing non-Hodgkin lymphoma characterized by remission and relapse, becoming harder to treat over time. Roche continues to innovate in hematology, offering a robust pipeline and portfolio of medicines for various blood diseases.